SWTX - SpringWorks Therapeutics, Inc.

46.99
0.010   0.021%

Share volume: 5,010,844
Last Updated: 06-30-2025
Pharmaceutical Products/Biological Products, Except Diagnostic Substances: 0.31%

PREVIOUS CLOSE
CHG
CHG%
$46.98
0.01
0.00%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
21%
Profitability 25%
Dept financing 1%
Liquidity 50%
Performance 15%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
0   0%
1 Month
0   0%
3 Months
0   0%
6 Months
0   0%
1 Year
-8.54%
2 Year
-5.55%
Key data
Stock price
$46.99
P/E Ratio 
0.00
DAY RANGE
$46.98 - $47.01
EPS 
-$3.87
52 WEEK RANGE
$32.83 - $53.51
52 WEEK CHANGE
-$7.12
MARKET CAP 
3.307 B
YIELD 
N/A
SHARES OUTSTANDING 
75.323 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
08-06-2025
BETA 
0.68
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
N/A
AVERAGE 30 VOLUME 
N/A
Company detail
CEO: Saqib Islam
Region: US
Website: springworkstx.com
Employees: 230
IPO year: 2019
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Biological Products, Except Diagnostic Substances
Sector: Manufacturing

SpringWorks Therapeutics, Inc. acquires, develops, and commercializes medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is nirogacestat, an oral small molecule gamma secretase inhibitor that is in Phase III clinical trial for the treatment of desmoid tumors.

Recent news